Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy
批准号:
8503392
负责人:
Salomeh Keyhani
金额:
$77.06万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2018-04-30
关键词:
AddressAgeAtrial FibrillationBlood PressureBlood VesselsCarotid ArteriesCarotid EndarterectomyCarotid StenosisCessation of lifeClinicalClinical TrialsCohort StudiesCommunitiesDataDevelopmentDiabetes MellitusDiagnosisDiseaseEarly InterventionEffectiveness of InterventionsEnrollmentHyperlipidemiaIntentionInterventionMedicalMedicareMyocardial InfarctionOperative Surgical ProceduresOutcomePatientsPerioperativeProceduresPublishingRandomized Controlled TrialsRegimenReportingRiskRisk FactorsStrokeStroke preventionSubgroupSurgical complicationTechniquesTherapeutic InterventionTimeTransient Ischemic AttackVascular DiseasesVeteransarmbasecohortcomparative effectivenesscompare effectivenessdesignhealth administrationhuman old age (65+)hypertension controlimprovedprimary outcomepublic health relevancerisk benefit ratiotreatment strategy
中文摘要
描述(由申请人提供):随机对照试验(RCT)已经证实,颈动脉内膜切除术(CEA)在预防无症状和有症状颈动脉狭窄患者卒中方面上级药物治疗。然而,虽然大多数接受颈动脉血运重建的患者接受无症状疾病的治疗,但无症状疾病患者的血运重建获益相当有限。此外,临床试验开始于大约20年前,在此期间,由于新的药理学进展,如高效他汀类药物,改善的抗血小板方案,以及更好地控制高血压,高脂血症和糖尿病,这种血管疾病的药物治疗有了很大的改善。同时,随着CEA手术并发症发生率的降低,颈动脉支架植入术(CAS)在无症状颈动脉狭窄的治疗中越来越受欢迎。虽然最近的试验只集中在比较CEA和CAS,但与医学管理的颈动脉狭窄相关的卒中率下降导致许多人质疑血运重建术是否上级积极的血管风险因素控制。一个三臂随机对照试验可以回答这个问题,但这样的研究将是非常昂贵的,在很长一段时间内不能提供答案,并且可能只招募最健康的患者的子集通常在随机对照试验中研究。自从发表了第一个证明CEA优于药物治疗的RCT以来,人们一直担心试验中观察到的适度获益可能无法在社区中重现。为了解决无症状颈动脉狭窄患者中CEA是否仍上级于药物治疗以及CAS是否上级于药物治疗的持续争论(从未在RCT中进行过评估),我们建议使用合并的退伍军人健康管理局和医疗保险对6000名患者进行回顾性队列研究,以检查初始药物治疗与早期颈动脉干预的比较有效性数据我们将专门将每种血运重建策略与药物治疗进行比较,并检查许多关键变量(例如年龄、是否存在房颤)对干预与药物治疗相比的相对有效性的影响。我们将使用先进的统计技术来克服药物治疗和干预队列中观察到的和未观察到的差异。我们将比较2005年至2008年入组的3175例药物治疗患者、1500例接受CEA治疗的患者和1325例接受CAS治疗的患者的30天和5年结局。我们的总体假设是,药物治疗已经改善到一定程度,只有某些亚组的患者可能受益于血运重建,对许多患者来说,药物治疗可能是首选的治疗策略。
英文摘要
DESCRIPTION (provided by applicant): Randomized controlled trials (RCTs) have established that carotid endarterectomy (CEA) is superior to medical therapy in preventing stroke in both asymptomatic and symptomatic patients with carotid stenosis. However, while the majority of patients who undergo carotid revascularization receive treatment for asymptomatic disease, the benefit of revascularization for patients with asymptomatic disease is quite modest. In addition, the clinical trials were initiated about 20 years ago, and in the intervening period, medical therapy has greatly improved for this vascular disease due to new pharmacological advances such as high potency statins, improved antiplatelet regimens, and better control of hypertension, hyperlipidemia and diabetes. In parallel, as the surgical complication rate for CEA has decreased, the use of carotid artery stenting (CAS) has been gaining favor in the treatment of asymptomatic carotid stenosis. While recent trials have focused exclusively on comparing CEA to CAS, the declining stroke rate associated with medically managed carotid stenosis has led many to question whether either revascularization procedure is superior to aggressive vascular risk factor control. A three-arm RCT could answer this question, but such a study would be very expensive, not provide answers for a long time, and might only enroll the subset of healthiest patients typically studied in an RCT. Since the first RCT was published that demonstrated the superiority of CEA compared to medical therapy there has been a concern that the modest benefit observed in the trials may not be reproducible in the community. To address the ongoing debate of whether among patients with asymptomatic carotid stenosis, CEA is still superior to medical therapy and whether CAS is superior to medical therapy (which has never been evaluated in an RCT), we propose to examine the comparative effectiveness of initial medical therapy compared to early carotid intervention in a retrospective cohort study of 6000 patients using merged Veteran's Health Administration and Medicare data. We will specifically compare each revascularization strategy to medical therapy and also examine the impact of a number of key variables (e.g. age, presence of atrial fibrillation) on the comparative effectiveness of intervention compared to medical therapy. We will use advanced statistical techniques to overcome observed and unobserved differences in the medical therapy and intervention cohorts. We will compare the 30-day and 5 year outcomes of 3175 patients managed medically, 1500 patients who received CEA, and 1325 patients who received CAS entering the cohort from 2005 to 2008. Our overarching hypothesis is that medical therapy has improved to a degree that only certain subgroups of patients may benefit from revascularization and that for many patients medical therapy may be the preferred treatment strategy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury
-
批准号:10132223
-
项目类别:
-
资助金额:$59.78万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury
-
批准号:10576324
-
项目类别:
-
资助金额:$56.27万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy
-
批准号:10312709
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Risks of Cannabis Use Among Veterans on Long-term Opioid Therapy
-
批准号:10817659
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Marijuana Use in Older Adults: Health, Function and Fall-Related Injury
-
批准号:10360509
-
项目类别:
-
资助金额:$57.81万
-
财政年份:2019
-
负责人:Salomeh Keyhani
-
依托单位:
Impact of marijuana on adherence, risk factor control and cardiovascular events
-
批准号:9404476
-
项目类别:
-
资助金额:$72.99万
-
财政年份:2017
-
负责人:Salomeh Keyhani
-
依托单位:
An Evaluation of Novel Domains for Predicting 30-Day Readmission
-
批准号:8576427
-
项目类别:
-
资助金额:$73.86万
-
财政年份:2013
-
负责人:Salomeh Keyhani
-
依托单位:
Comparative Effectiveness of Carotid Artery Revascularization vs Medical Therapy
-
批准号:8666037
-
项目类别:
-
资助金额:$73.33万
-
财政年份:2013
-
负责人:Salomeh Keyhani
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: